

PHARMESIS INTERNATIONAL LTD.
(the “**Company**”)
(Incorporated in the Republic of Singapore)
(Co. Registration No.: 200309641E)

**THE PROPOSED ACQUISITION OF 30% OF THE EQUITY INTEREST IN SICHUAN LONGLIFE –
EXTENSION OF LONG STOP DATE**

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company’s announcement dated 31 December 2018.

The Board refers to the announcement made on 31 December 2018, in relation to the entry by 成都国嘉联合制药有限公司 (Chengdu Kinna Pharmaceutical Co., Ltd) (the “**Purchaser**”), a wholly-owned subsidiary of the Company, into a conditional sale and purchase agreement (the “**SPA**”) to acquire 30% of the equity interest (“**Equity Interest**”) in the registered capital of 四川古蔺肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd) (“**Sichuan Longlife**”) from 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.) (the “**Vendor**”) (the “**Proposed Acquisition**”).

The Board wishes to announce that the Purchaser and the Vendor of Sichuan Longlife have mutually agreed in writing to extend the deadline for obtaining the requisite approval(s) from the Company’s Shareholders under Chapters 9 and 10 of the Listing Manual at the EGM for, *inter alia*, the proposed acquisition of the 30% of the equity interest in the registered capital of Sichuan Longlife from 31 March 2019 to 30 June 2019.

The Company will make further announcements on the Proposed Acquisition as and when appropriate.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer

29 March 2019